BioSpace News Archive

Capstone Headwaters LLC, a leading international investment banking firm, announced that it has successfully advised Gibraltar Laboratories (“Gibraltar”) on its acquisition by Sotera Health.

Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced encouraging top-line results for its clinical Phase II/III trial with orally administered arimoclomol for the treatment of patients with Niemann-Pick disease Type C (NPC).

Today the U.S. Food and Drug Administration permitted marketing of ClonoSEQ assay, a next generation sequencing (NGS)-based test for minimal residual disease (MRD) in patients with acute lymphoblastic leukemia (ALL) or multiple myeloma. MRD is a measure of the amount of cancer cells remaining in a person’s bone marrow.

Ahead of the inaugural edition of bioLIVE – the bioprocessing and manufacturing event opening October (9-11) in Madrid – CPhI Worldwide announces the bio findings of its annual report, which foresees much greater efficiency in biomanufacturing and an increased exchange of ideas across small and large molecule industries.

Libtayo is the third anti-PD-1 approved in the U.S.

New drug targets PD-1 pathway

Patients need to check their device to confirm that it can be removed from the carrier tube with ease

PTC Therapeutics, Inc. today announced that on September 25, 2018 it approved non-statutory stock options to purchase an aggregate of 122,200 shares of its common stock to 33 new employees.

Libtayo is the third anti-PD-1 approved in the U.S.

Training will take place through the “Rensselaer Health INCITE Pipeline”